2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/1on664om2hmh1.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T712e,

Summary Table

Category	Detail
Risk Factors	Heart failure (systolic or diastolic), acute MI, valvular disease (especially mitral), hypertensive crisis, volume overload (renal failure, excessive IV fluids), sepsis, pneumonia, pancreatitis, trauma, high altitude, CNS injury
Etiology	Cardiogenic: elevated pulmonary capillary hydrostatic pressure from left-sided heart failure. Non-cardiogenic: disrupted alveolar-capillary membrane permeability (ARDS, sepsis, aspiration, inhalation injury)
Patient Presentation	Acute dyspnea, orthopnea, paroxysmal nocturnal dyspnea (PND), pink frothy sputum, anxiety, diaphoresis
Classic Physical Exam	Bilateral crackles (rales) on auscultation, S3 gallop, elevated JVP, peripheral edema, tachypnea, tachycardia, hypoxia. In non-cardiogenic: no S3 or JVP elevation
Key Diagnostic Results	CXR: bilateral alveolar infiltrates, cephalization of pulmonary vessels, Kerley B lines, peribronchial cuffing, pleural effusions. Elevated BNP/NT-proBNP in cardiogenic type. Echocardiography shows reduced EF or diastolic dysfunction. Swan-Ganz: PCWP > 18 mmHg (cardiogenic) vs. < 18 mmHg (non-cardiogenic)
Management	Acute cardiogenic: upright positioning, supplemental O2, IV loop diuretics (furosemide), IV nitroglycerin for afterload reduction, non-invasive positive pressure ventilation (CPAP/BiPAP). Non-cardiogenic (ARDS): low tidal volume ventilation, treat underlying cause
Keywords	"Pink frothy sputum," "bilateral crackles," "orthopnea," "S3 gallop," "Kerley B lines," "bat-wing infiltrates," "cephalization," "paroxysmal nocturnal dyspnea"

1. Pathophysiology

Pulmonary edema is the abnormal accumulation of fluid in the extravascular compartments of the lung, including the interstitium and alveolar spaces. To understand why this happens, you must recall the Starling equation, which governs fluid movement across the capillary membrane:

$$Q = K_f \left[(P_c - P_i) - \sigma(\pi_c - \pi_i)\right]$$

where $Q$ is the net fluid filtration, $K_f$ is the filtration coefficient (a measure of membrane permeability), $P_c$ is capillary hydrostatic pressure, $P_i$ is interstitial hydrostatic pressure, $\sigma$ is the reflection coefficient, $\pi_c$ is capillary oncotic pressure, and $\pi_i$ is interstitial oncotic pressure.

Cardiogenic pulmonary edema arises when left-sided heart failure causes a rise in left atrial pressure, which transmits backward into the pulmonary veins and capillaries, elevating $P_c$. When the capillary hydrostatic pressure exceeds the oncotic pressure holding fluid in the vessel, fluid is driven out into the interstitium first (causing interstitial edema with Kerley B lines on imaging), and then into the alveoli themselves (causing alveolar flooding). This is why the patient develops crackles on auscultation: the opening of fluid-filled alveoli during inspiration creates the sound. The pink frothy sputum results from protein-rich fluid mixing with surfactant and small amounts of red blood cells in the alveoli. Orthopnea and PND occur because recumbency increases venous return, further elevating pulmonary capillary pressure in an already-failing left ventricle.

Non-cardiogenic pulmonary edema occurs through a fundamentally different mechanism. Here, the $K_f$ (membrane permeability) increases due to direct injury to the alveolar-capillary barrier. Inflammatory mediators (cytokines, neutrophil proteases, reactive oxygen species) damage the endothelial and epithelial layers, allowing protein-rich fluid to leak into the alveoli even at normal hydrostatic pressures. This is the hallmark of ARDS. Because the fluid is protein-rich and the barrier is structurally damaged, it does not respond to diuresis the way cardiogenic edema does.

A third and less common but highly testable category is neurogenic pulmonary edema, which occurs after acute CNS injury (subarachnoid hemorrhage, traumatic brain injury, seizures). The mechanism involves a catecholamine surge that causes sudden, intense pulmonary vasoconstriction and a transient spike in hydrostatic pressure, along with some degree of permeability injury.

2. Classification and Clinical Manifestation

Type	Mechanism	Onset	Sputum	Cardiac Signs	PCWP	Edema Fluid Protein
Cardiogenic	Elevated hydrostatic pressure from LV failure	Gradual or acute (flash edema)	Pink, frothy	S3 gallop, elevated JVP, peripheral edema	> 18 mmHg	Low protein (transudate)
Non-cardiogenic (ARDS)	Increased capillary permeability from inflammatory injury	Usually within 6 to 72 hours of insult	May be frothy but not pink	Absent cardiac signs	< 18 mmHg	High protein (exudate)
Neurogenic	Catecholamine surge after CNS injury	Minutes to hours after CNS event	Pink, frothy	Usually absent	Variable (can be elevated transiently)	Mixed
High-altitude (HAPE)	Hypoxic pulmonary vasoconstriction causing uneven perfusion	2 to 5 days after ascent above 2500 m	Pink, frothy	No underlying cardiac disease	Normal	High protein
Re-expansion	Rapid re-expansion of collapsed lung	Within hours of thoracentesis or chest tube	Frothy	Absent	Normal	High protein
Negative-pressure	Post-obstructive inspiration against closed glottis (laryngospasm)	Immediate post-extubation or relief of upper airway obstruction	Frothy	Absent	Normal	Variable

Clinical Staging of Cardiogenic Pulmonary Edema

Stage	Location of Fluid	CXR Finding	Symptoms
Stage 1: Redistribution	Fluid shifts to upper lobes	Cephalization of pulmonary vessels	Mild dyspnea on exertion
Stage 2: Interstitial edema	Interstitial space (peribronchial, perivascular, septal)	Kerley B lines, peribronchial cuffing, hazy perihilar regions	Worsening dyspnea, orthopnea
Stage 3: Alveolar edema	Alveolar spaces flooded	Bilateral "bat-wing" or "butterfly" alveolar opacities, air bronchograms	Severe dyspnea at rest, pink frothy sputum, respiratory failure

3. Diagnostic Workup

Test	Role	Key Finding
Chest X-ray	Best Initial Test	Cephalization, Kerley B lines, bat-wing opacities, pleural effusions
BNP / NT-proBNP	Differentiate cardiogenic from non-cardiogenic	BNP > 400 pg/mL or NT-proBNP > 900 pg/mL strongly suggests cardiogenic cause
Echocardiography	Assess cardiac function	Reduced EF (systolic failure), diastolic dysfunction, valvular abnormalities
Pulse oximetry / ABG	Assess oxygenation	Hypoxemia; calculate $A\text{-}a$ gradient (elevated in both types)
Troponin	Rule out acute MI as precipitant	Elevated if acute coronary syndrome is the trigger
ECG	Identify arrhythmia or ischemia	ST changes, atrial fibrillation, LVH pattern
Swan-Ganz catheterization	Gold Standard for differentiating types	PCWP > 18 mmHg = cardiogenic; PCWP < 18 mmHg = non-cardiogenic

The chest X-ray is the best initial test when a patient presents with acute dyspnea and suspected pulmonary edema. In cardiogenic edema, look for the classic radiographic progression: vascular cephalization (redistribution of blood flow to the upper lobes), followed by interstitial markings (Kerley B lines, which are short horizontal lines at the lung periphery caused by fluid in interlobular septa), and finally bilateral alveolar opacities in a "bat-wing" or "butterfly" distribution. Cardiogenic edema also frequently shows bilateral pleural effusions and an enlarged cardiac silhouette. In non-cardiogenic edema (ARDS), the infiltrates tend to be more diffuse and peripheral without cardiomegaly or effusions.

BNP and NT-proBNP levels are critical for distinguishing cardiogenic from non-cardiogenic causes at the bedside. A BNP < 100 pg/mL essentially rules out heart failure as the cause. A BNP > 400 pg/mL makes cardiogenic edema highly likely. Values between 100 and 400 pg/mL fall in a gray zone and require clinical correlation. Be aware that renal failure elevates BNP regardless of cardiac function, and obesity lowers BNP (fat tissue clears natriuretic peptides), which can create falsely reassuring levels.

Echocardiography should be obtained to evaluate left ventricular systolic function (ejection fraction), diastolic filling patterns, and valvular pathology. This is especially important to identify treatable precipitants such as acute mitral regurgitation, aortic stenosis, or wall motion abnormalities suggesting acute MI.

The $A\text{-}a$ gradient is calculated as:

$$A\text{-}a\ \text{gradient} = \left[FiO_2 \times (P_{atm} - P_{H_2O}) - \frac{PaCO_2}{R}\right] - PaO_2$$

An elevated gradient confirms a parenchymal process (pulmonary edema, ARDS, PE) as opposed to hypoventilation, which has a normal gradient.

The Swan-Ganz catheter (right heart catheterization) remains the gold standard for differentiating cardiogenic from non-cardiogenic pulmonary edema. A pulmonary capillary wedge pressure (PCWP) greater than 18 mmHg confirms a cardiogenic etiology. However, this is an invasive test and is reserved for cases where the diagnosis remains unclear after non-invasive workup or when the patient is hemodynamically unstable and requires precise hemodynamic monitoring.

4. Management and Treatment

Setting	Intervention	Details
Immediate stabilization	Positioning	Sit the patient upright (reduces venous return)
	Oxygen	Supplemental O2 to maintain SpO2 > 90%
	Non-invasive ventilation	CPAP or BiPAP (reduces preload, reduces work of breathing, improves oxygenation)
	IV Furosemide	20 to 80 mg IV bolus; onset within 5 minutes (venodilation) and 20 to 30 minutes (diuresis)
	IV Nitroglycerin	Start at 5 to 10 mcg/min, titrate upward; reduces preload and afterload
Hypotension / cardiogenic shock	Dobutamine	2 to 20 mcg/kg/min; positive inotrope
	Milrinone	0.375 to 0.75 mcg/kg/min; inotrope + vasodilator (useful if on beta-blockers)
	Mechanical support	Intra-aortic balloon pump (IABP) or percutaneous VAD if refractory
Hypertensive crisis trigger	Nitroprusside	0.3 to 5 mcg/kg/min; afterload reduction in severe hypertensive flash edema
Long-term (HFrEF)	ACE inhibitor or ARB	Mortality benefit; start once stable
	Beta-blocker	Carvedilol, metoprolol succinate, or bisoprolol; start when euvolemic
	Aldosterone antagonist	Spironolactone 25 to 50 mg daily (EF < 35%, NYHA II to IV)
	SGLT2 inhibitor	Dapagliflozin or empagliflozin; mortality and hospitalization benefit
	Hydralazine + Isosorbide dinitrate	If ACEi/ARB not tolerated, or as add-on in Black patients
Non-cardiogenic (ARDS)	Low tidal volume ventilation	6 mL/kg ideal body weight; plateau pressure < 30 cmH2O
	PEEP	Titrate to improve oxygenation and prevent alveolar collapse
	Prone positioning	If $PaO_2/FiO_2$ < 150 mmHg
	Treat underlying cause	Antibiotics for sepsis/pneumonia, supportive care

Management Walkthrough

Acute cardiogenic pulmonary edema is a medical emergency. The first step is to sit the patient upright to reduce venous return and lower pulmonary capillary pressure. Supplemental oxygen should be provided immediately, and if the patient remains hypoxic or has significant respiratory distress, non-invasive positive pressure ventilation (CPAP at 5 to 10 cmH2O, or BiPAP) should be applied. CPAP/BiPAP works by increasing intrathoracic pressure, which reduces preload, lowers transmural left ventricular pressure (effectively reducing afterload), and recruits fluid-filled alveoli. Multiple trials have shown that early non-invasive ventilation reduces intubation rates and mortality.

IV furosemide is the cornerstone of pharmacologic management. Give 20 to 80 mg IV as a bolus (if the patient is already on chronic oral furosemide, the initial IV dose should be equal to or greater than their home dose). Furosemide has a biphasic mechanism: it causes venodilation within 5 minutes (reducing preload before diuresis even begins) and then produces diuresis at 20 to 30 minutes. If the response is inadequate after 20 minutes, the dose can be doubled. Monitor urine output closely; aim for at least 0.5 to 1 mL/kg/hour.

IV nitroglycerin is started at 5 to 10 mcg/min and titrated upward every 5 minutes. It primarily reduces preload through venodilation, and at higher doses, it also reduces afterload. It is contraindicated if the patient has taken phosphodiesterase-5 inhibitors (sildenafil, tadalafil) within 24 to 48 hours, or if systolic blood pressure is below 90 mmHg.

If the patient is hypotensive or in cardiogenic shock, diuretics and vasodilators are contraindicated. Instead, start dobutamine (a beta-1 agonist/inotrope) at 2 to 20 mcg/kg/min. If the patient is on chronic beta-blocker therapy, milrinone (a phosphodiesterase-3 inhibitor) is preferred because its mechanism bypasses the beta receptor. In refractory cardiogenic shock, consider mechanical circulatory support.

Long-term management of heart failure with reduced ejection fraction (HFrEF) follows the four-pillar regimen: ACE inhibitor or ARB (or ARNI), beta-blocker, aldosterone antagonist, and SGLT2 inhibitor. These are all started once the patient is clinically stable and euvolemic. Beta-blockers must never be started during an acute decompensation episode because they can worsen heart failure acutely. They are initiated or resumed only after the patient is stable and dry.

For non-cardiogenic pulmonary edema (ARDS), diuretics are generally not helpful because the edema is caused by permeability, not pressure. Management centers on lung-protective ventilation with low tidal volumes (6 mL/kg of ideal body weight, not actual body weight), keeping plateau pressure below 30 cmH2O, and applying appropriate PEEP. If the $PaO_2/FiO_2$ ratio remains below 150 despite optimization, prone positioning for at least 12 to 16 hours per day has a mortality benefit. The underlying cause (sepsis, aspiration, pancreatitis) must be treated concurrently.

5. Differential Diagnosis and Distractors

Differential	Why It Is Similar	Key Discriminator
Pneumonia	Bilateral infiltrates on CXR, dyspnea, crackles, hypoxia	Fever, productive purulent sputum, focal or lobar consolidation, elevated procalcitonin; no elevated BNP, no orthopnea, no S3
ARDS	Bilateral infiltrates, severe hypoxemia, respiratory failure	No cardiomegaly, no cephalization, PCWP < 18 mmHg, BNP normal, preceded by a known insult (sepsis, aspiration, trauma) within 7 days
Pulmonary embolism	Acute dyspnea, hypoxemia, tachycardia	Sudden onset, pleuritic chest pain, clear lung fields on CXR (or Hampton hump/Westermark sign), elevated D-dimer, CT angiography confirms clot. No bilateral infiltrates
Asthma / COPD exacerbation	Acute dyspnea, wheezing, tachypnea	Expiratory wheezing (not crackles), hyperinflation on CXR, history of asthma/COPD, normal BNP, obstructive pattern on spirometry
Nephrotic syndrome (volume overload)	Peripheral edema, possible pleural effusions, dyspnea	Heavy proteinuria (> 3.5 g/day), hypoalbuminemia, normal cardiac function on echo, edema is primarily caused by low oncotic pressure rather than cardiac failure
Mitral stenosis	Dyspnea, orthopnea, pulmonary congestion, hemoptysis	Opening snap and low-pitched diastolic rumble at the apex, normal or small LV cavity, dilated left atrium, often associated with history of rheumatic fever

6. Traps and High-Yield Pearls

The most common way students lose points on pulmonary edema questions is by failing to differentiate cardiogenic from non-cardiogenic edema. Both present with bilateral infiltrates and hypoxemia, and the vignette may not immediately make the distinction obvious. The critical pivot point is the BNP level and PCWP value. If BNP is normal and the clinical context includes a recent insult (sepsis, aspiration, trauma, pancreatitis, transfusion), think ARDS. If BNP is elevated and the patient has an S3 gallop, JVP elevation, or peripheral edema, think cardiogenic. When the vignette gives you a Swan-Ganz reading, a PCWP above 18 mmHg confirms cardiogenic etiology.

Another frequent trap involves "flash" pulmonary edema. A patient presents with sudden-onset severe dyspnea and bilateral pulmonary edema but has a preserved ejection fraction on echocardiography. Students often dismiss cardiogenic edema because the EF is normal. Flash pulmonary edema is classically triggered by acute hypertensive crisis, bilateral renal artery stenosis, or acute mitral regurgitation. The left ventricle may contract normally, but diastolic dysfunction or acute afterload mismatch causes the backup of pressure into the pulmonary vasculature. Always consider diastolic heart failure (HFpEF) and valvular emergencies when EF is preserved.

Students also stumble on management sequencing. In an acutely hypoxic and dyspneic patient, the next best step is non-invasive positive pressure ventilation and IV furosemide, not intubation (unless the patient is obtunded or in respiratory arrest). Starting beta-blockers during an acute decompensation episode is a classic wrong answer. And administering large volumes of IV fluids to a patient with bilateral pulmonary infiltrates before confirming that the edema is non-cardiogenic is a dangerous mistake that worsens cardiogenic edema.

Finally, remember that morphine, once considered a standard treatment for acute pulmonary edema, is now discouraged in current guidelines. Multiple studies have associated morphine use with increased intubation rates, ICU admissions, and mortality. If morphine appears as an answer choice alongside CPAP, furosemide, or nitroglycerin, it is almost certainly the wrong answer.

The core competency being tested in pulmonary edema questions is the ability to rapidly categorize the type of edema based on clinical and diagnostic clues, choose the correct initial management based on hemodynamic status (hypertensive vs. normotensive vs. hypotensive), and avoid outdated or harmful interventions.

1d:["$","$L2c",null,{"article":{"id":"68669238-bf32-465a-a325-57ac38e9adb6","title":"Edema Paru","content":"$2d","category":"Respirologi","created_at":"2026-09-07T02:50:21.483974+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]